Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

NCT05024045 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05024045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05024045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2021
Completion date
March 2, 2026
Enrollment
27 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, leukemia, lymphocytic, chronic, b-cell, lymphoma, b-cell marginal zone, lymphoma, mantle-cell, lymphoma, non-hodgkin, multiple myeloma, waldenstrom macroglobulinemia